safety of glp 1 Efficacy and GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis Glucagon-Like Peptide-1 Agonist Use in

A post-hoc analysis of SURMOUNT-5 estimated a larger reduction in predicted 10-year cardiovascular risk with tirzepatide (23.7%) than semaglutide (13.6%), but these are modeled projections, not measured outcomes

GLP-1 Glucagon-like peptide-1

In February 2024, we announced that the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo

But there are specific modifications worth making to accommodate the GI sensitivity and reduced appetite that semaglutide creates

If youre goal is muscle building start on the higher end of that spectrum